NextCure Inc (NXTC) Gets a Buy Rating from Morgan Stanley

By Ryan Adsit

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on NextCure Inc (NXTCResearch Report) yesterday and set a price target of $33. The company’s shares closed last Monday at $26.71, close to its 52-week high of $27.89.

According to TipRanks.com, Hung is a 3-star analyst with an average return of 9.1% and a 56.5% success rate. Hung covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Voyager Therapeutics Inc, and Prevail Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NextCure Inc with a $25.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.89 and a one-year low of $13.86. Currently, NextCure Inc has an average volume of 74.16K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NXTC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.